Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06083467 · ClinicalTrials.gov registry record · NA
CW2IP2: Imaging and Diagnostic Assessments
A NA study of Tauopathies, sponsored by University of Pennsylvania.
- Recruiting
- Registry status
- NA
- Development phase
- 94
- Enrollment target
- 1
- Study location
NCT06083467: Recruiting NA study of Tauopathies, sponsored by University of Pennsylvania.
NCT06083467 is a NA study of Tauopathies that is actively recruiting participants, run by University of Pennsylvania. The registered enrollment target is 94 participants, above the 65-participant average among 5 other Tauopathies trials with a reported enrollment target (45% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06083467, a NA study of Tauopathies, is actively recruiting participants, sponsored by University of Pennsylvania.
- RECRUITING
- Registry status
- NA
- Development phase
- 94 participants
- Enrollment target
- 1
- Study location
Study Summary
This current protocol will provide the key data to help determine the specificity of our to-be-developed radiotracers by implementing a multi-site diagnostic assessment core and PET imaging of A-beta amyloid (may be completed at some sites as part of another protocol) that is commonly deposited in the brains of people with Parkinson's Disease (PD), Multiple System Atrophy (MSA), Progressive Supranuclear Palsy (PSP) or Frontotemporal Dementia (FTD) as well as healthy controls. This multicenter U19 grant is centered at U Pennsylvania (U Penn) (PI: Robert Mach) in collaboration with U Pittsburgh (Pitt), Yale University, U of California at San Francisco (UCSF) and Washington University in St. Louis (WU). U Penn will act as the single IRB of Record (sIRB) for this multi-center project and subjects will be recruited from all sites.
Primary Outcome
The primary outcome is a diagnosis classification of a neurodegenerative disease. Participants will be referred based on a clinical evaluation suggesting possible Parkinson Disease, Progressive Supranuclear Palsy, Multiple System Atrophy, Frontotemporal Lobar Degeneration, or other neurodegenerative disease or as a likely healthy control. Participants will have cognitive testing, physical examination, imaging studies, and record review, which will be used to determine the probable diagnosis. If
Conditions Studied
Interventions
- DIAGNOSTIC_TEST Brain MRI Scan
- BEHAVIORAL Neurologic exam
Study Locations (1)
Pennsylvania
- University of Pennsylvania - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 94 participants |
| Start Date | 2023-07-20 |
| Est. Completion | 2028-07-31 |
| Phase | NA |
What NCT06083467 shows while recruiting
NCT06083467 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 94 participants, a relatively small participant target, above the 65-participant average among 5 other Tauopathies trials with a reported enrollment target (45% higher).
The record links to 1 condition, with Tauopathies appearing as the primary indexed condition, and to 2 interventions - of which Brain MRI Scan is the first listed.
NCT06083467 reports a single indexed study location in Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT06083467 about?
NCT06083467 is a clinical study titled "CW2IP2: Imaging and Diagnostic Assessments". This current protocol will provide the key data to help determine the specificity of our to-be-developed radiotracers by implementing a multi-site diagnostic assessment core and PET imaging of A-beta amyloid (may be completed at some sites as part of another protocol) that is commonly deposited in t...
What is the current status of trial NCT06083467?
This trial is currently recruiting. It is a NA study. The enrollment target is 94 participants. The study started on 2023-07-20. Estimated completion is 2028-07-31.
What conditions does trial NCT06083467 study?
This clinical trial studies the following conditions: Tauopathies.
What interventions are being tested in trial NCT06083467?
The interventions under investigation include: Brain MRI Scan (DIAGNOSTIC_TEST), Neurologic exam (BEHAVIORAL).
Who is sponsoring clinical trial NCT06083467?
This trial is sponsored by University of Pennsylvania, which has 1,423 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06083467 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Tauopathies
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Harmony at Home: A Pilot Telehealth Program for Rural ADRD Caregivers
COMPLETED · NA
-
Study of Biodistribution, Metabolism, Excretion and Brain Uptake of 11C-HY-2-15
RECRUITING · Early Phase 1
-
Study of Biodistribution, Metabolism, Excretion and Brain Uptake11C-M503
RECRUITING · Early Phase 1
-
Study of Biodistribution, Metabolism, Excretion and Brain Uptake 18F-JSS20-183A
RECRUITING · Early Phase 1
-
Evaluation of [18F]MNI-777 PET as a Marker of Tau Pathology in Subjects With Tauopathies Compared to Healthy Subjects
COMPLETED · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03747146 · 94 participants · NA
Enhanced Recovery After Surgery (ERAS) Total Knee Replacement (TKR) With a Transitional Pain Service
- NCT04061421 · 94 participants · Phase 1
Active Myeloid Target Compound Combinations in MDS/MPN Overlap Syndromes Overlap Syndromes (ABNL-MARRO)
- NCT04205968 · 94 participants · Phase 2
Ramucirumab and Paclitaxel or FOLFIRI in Advanced Small Bowel Cancers
- NCT04464759 · 94 participants · Phase 1
A Study of Nivolumab and Hydroxychloroquine or Nivolumab/Ipilimumab and Hydroxychloroquine in Advanced Melanoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI